Temas de interès de la CIPIH
Carga de morbilidad
La identificación de las principales causas de morbilidad y mortalidad en los países en desarrollo y de los costos humanos, sociales y económicos que conllevan es una cuestión importante. Las prioridades de investigación y desarrollo e innovación deben comprender desde la profundización en el conocimiento de la carga de morbilidad en los países en desarrollo hasta la manera de usar las nuevas tecnologías para solucionar ese problema. Otra cuestión es si los medicamentos de los que se dispone actualmente para tratar determinadas enfermedades son de hecho adecuados.
Documentos
-
10/90 Report on Health Research 2003-2004
-
Informe sobre la salud en el mundo 2002 "Reducir los riesgos y promover una vida sana"
-
The effect of the AIDS epidemic on economic welfare in sub-Saharan Africa | By D.T. Jamison, J.D. Sachs, J. Wang | CMH Working paper series, paper no. WG1:13 | 2001
-
Interventions to reduce tuberculosis mortality and transmission in low and middle income countries: effectiveness, cost-effectiveness and constraints to scaling up | By M.W. Borgdorff, K. Floyd, J.F. Broekmans | CMH Working paper series, paper no.WG6:8 | 2001
-
he evidence base for interventions to reduce under five mortality in low and middle income countries | By H. Gelband, S. Stansfield | CMH Working paper series, paper no.WG5:9 | 2001
-
Note on the health impact of water and sanitation services | By L. Vaz, P. Jha | CMH Working paper series, paper no.WG5:23 | 2001
-
The Global Burden of Chronic Diseases: Overcoming Impediments to Prevention and Control | By Derek Yach, Corinna Hawkes, C. Linn Gould, Karen J. Hofman | JAMA, June 2, 2004—Vol 291, No. 21 pp. 2616 -2622
-
Understanding the Burden of Disease: A Global Perspective | The Pfizer Journal, Global Edition Volume 1 No 1 | 2000
-
10/90 Report on Health Research 2003-2004 | Global Forum for Health Research | Geneva, 2004
-
Evidence-Based Global Health | P. Buekens, G. Keusch, J. Belizan, Z. A. Bhutta | JAMA Vol 291, 21, June 2004
-
Drug Development for Neglected Diseases: a Deficient Market and a Public Health Policy Failure | By P. Trouiller et al | The Lancet, vol. 359, pp.2188 – 94 | 2002
-
Working paper on priority infectious diseases requiring additional R&D | WHO- IFPMA Round Table | Geneva, 2001
-
Genomics and World Health | Report of the Advisory Committee on World Health | Geneva, 2002